CINXE.COM

<?xml version="1.0" encoding="ISO-8859-1"?> <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:admin="http://webns.net/mvcb/" > <channel rdf:about="http://jnm.snmjournals.org"> <title>: Most-Cited Full-Text Articles</title> <link>http://jnm.snmjournals.org</link> <description>Most-cited rankings are recalculated at the beginning of the month based on citations to articles on this journal site from articles in other HighWire-hosted journals.</description> <prism:coverDisplayDate>2025-03-04</prism:coverDisplayDate> <items> <rdf:Seq> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1117?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/711?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/767?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/738?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/669?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1417?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/2/236?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/71?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1154?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/574?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1171?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1259?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1083?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/79?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/731?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1252?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1831?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1295?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1164?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1024?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1202?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/117?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1109?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/618?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/5/735?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1744?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/12/1876?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1721?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/10/1610?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1049?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1456?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1069?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1737?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1399?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/625?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/579?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/717?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1087?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1036?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1210?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/10/1532?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1690?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/12/1899?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/2/252?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1320?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1166?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1352?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/9/1340?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/4/510?rss=1&ssource=mfc" /> <rdf:li rdf:resource="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/4/540?rss=1&ssource=mfc" /> </rdf:Seq> </items> </channel> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1117?rss=1&ssource=mfc"> <title><![CDATA[MIRD Pamphlet No. 28, Part 1: MIRDcalc--A Software Tool for Medical Internal Radiation Dosimetry]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1117?rss=1&ssource=mfc</link> <description><![CDATA[Adam L. Kesner Jul 1, 2023; 64:1117-1124 Special Contributions]]></description> <dc:creator>Adam L. Kesner</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.264225</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[MIRD Pamphlet No. 28, Part 1: MIRDcalc--A Software Tool for Medical Internal Radiation Dosimetry]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1124</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Special Contributions</prism:section> <prism:startingPage>1117</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/711?rss=1&ssource=mfc"> <title><![CDATA[Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/711?rss=1&ssource=mfc</link> <description><![CDATA[Nader Hirmas May 1, 2023; 64:711-716 Featured Article of the Month]]></description> <dc:creator>Nader Hirmas</dc:creator> <dc:date>2023-05-01</dc:date> <dc:identifier>10.2967/jnumed.122.264689</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities]]></dc:title> <prism:number>5</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>716</prism:endingPage> <prism:publicationDate>2023-05-01</prism:publicationDate> <prism:section>Featured Article of the Month</prism:section> <prism:startingPage>711</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/767?rss=1&ssource=mfc"> <title><![CDATA[Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/767?rss=1&ssource=mfc</link> <description><![CDATA[Julia Brosch-Lenz May 1, 2023; 64:767-774 Clinical Investigations]]></description> <dc:creator>Julia Brosch-Lenz</dc:creator> <dc:date>2023-05-01</dc:date> <dc:identifier>10.2967/jnumed.122.264594</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy]]></dc:title> <prism:number>5</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>774</prism:endingPage> <prism:publicationDate>2023-05-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>767</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/738?rss=1&ssource=mfc"> <title><![CDATA[Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/738?rss=1&ssource=mfc</link> <description><![CDATA[Robert Seifert May 1, 2023; 64:738-743 Clinical Investigations]]></description> <dc:creator>Robert Seifert</dc:creator> <dc:date>2023-05-01</dc:date> <dc:identifier>10.2967/jnumed.118.215434</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer]]></dc:title> <prism:number>5</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>743</prism:endingPage> <prism:publicationDate>2023-05-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>738</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/669?rss=1&ssource=mfc"> <title><![CDATA[What Is Theranostics?]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/669?rss=1&ssource=mfc</link> <description><![CDATA[Wolfgang A. Weber May 1, 2023; 64:669-670 Editor's Page]]></description> <dc:creator>Wolfgang A. Weber</dc:creator> <dc:date>2023-05-01</dc:date> <dc:identifier>10.2967/jnumed.123.265670</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[What Is Theranostics?]]></dc:title> <prism:number>5</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>670</prism:endingPage> <prism:publicationDate>2023-05-01</prism:publicationDate> <prism:section>Editor's Page</prism:section> <prism:startingPage>669</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1417?rss=1&ssource=mfc"> <title><![CDATA[SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1417?rss=1&ssource=mfc</link> <description><![CDATA[Thomas A. Hope Sep 1, 2023; 64:1417-1423 Practice Standards]]></description> <dc:creator>Thomas A. Hope</dc:creator> <dc:date>2023-09-01</dc:date> <dc:identifier>10.2967/jnumed.123.265952</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy]]></dc:title> <prism:number>9</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1423</prism:endingPage> <prism:publicationDate>2023-09-01</prism:publicationDate> <prism:section>Practice Standards</prism:section> <prism:startingPage>1417</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/2/236?rss=1&ssource=mfc"> <title><![CDATA[Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/2/236?rss=1&ssource=mfc</link> <description><![CDATA[Magdalena Mileva Feb 1, 2024; 65:236-244 Clinical Investigations]]></description> <dc:creator>Magdalena Mileva</dc:creator> <dc:date>2024-02-01</dc:date> <dc:identifier>10.2967/jnumed.123.265987</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study]]></dc:title> <prism:number>2</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>244</prism:endingPage> <prism:publicationDate>2024-02-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>236</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/71?rss=1&ssource=mfc"> <title><![CDATA[Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/71?rss=1&ssource=mfc</link> <description><![CDATA[Ken Herrmann Jan 1, 2024; 65:71-78 Clinical Investigations]]></description> <dc:creator>Ken Herrmann</dc:creator> <dc:date>2024-01-01</dc:date> <dc:identifier>10.2967/jnumed.123.265448</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy]]></dc:title> <prism:number>1</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>78</prism:endingPage> <prism:publicationDate>2024-01-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>71</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1154?rss=1&ssource=mfc"> <title><![CDATA[High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1154?rss=1&ssource=mfc</link> <description><![CDATA[Yiran Wang Jul 1, 2023; 64:1154-1161 Clinical Investigations]]></description> <dc:creator>Yiran Wang</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.264810</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1161</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1154</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/574?rss=1&ssource=mfc"> <title><![CDATA[Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/574?rss=1&ssource=mfc</link> <description><![CDATA[Kambiz Rahbar Apr 1, 2023; 64:574-578 Brief Communications]]></description> <dc:creator>Kambiz Rahbar</dc:creator> <dc:date>2023-04-01</dc:date> <dc:identifier>10.2967/jnumed.122.264456</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study]]></dc:title> <prism:number>4</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>578</prism:endingPage> <prism:publicationDate>2023-04-01</prism:publicationDate> <prism:section>Brief Communications</prism:section> <prism:startingPage>574</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1171?rss=1&ssource=mfc"> <title><![CDATA[The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1171?rss=1&ssource=mfc</link> <description><![CDATA[Arthur C. Macedo Aug 1, 2023; 64:1171-1178 State of the Art]]></description> <dc:creator>Arthur C. Macedo</dc:creator> <dc:date>2023-08-01</dc:date> <dc:identifier>10.2967/jnumed.122.265200</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework]]></dc:title> <prism:number>8</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1178</prism:endingPage> <prism:publicationDate>2023-08-01</prism:publicationDate> <prism:section>State of the Art</prism:section> <prism:startingPage>1171</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1259?rss=1&ssource=mfc"> <title><![CDATA[A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1259?rss=1&ssource=mfc</link> <description><![CDATA[Phillip H. Kuo Aug 1, 2023; 64:1259-1265 Clinical Investigations]]></description> <dc:creator>Phillip H. Kuo</dc:creator> <dc:date>2023-08-01</dc:date> <dc:identifier>10.2967/jnumed.122.265077</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy]]></dc:title> <prism:number>8</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1265</prism:endingPage> <prism:publicationDate>2023-08-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1259</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1083?rss=1&ssource=mfc"> <title><![CDATA[Regression of Myocardial 99mTc-DPD Uptake After Tafamidis Treatment of Cardiac Transthyretin Amyloidosis]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1083?rss=1&ssource=mfc</link> <description><![CDATA[Maria Papathanasiou Jul 1, 2023; 64:1083-1086 Brief Communications]]></description> <dc:creator>Maria Papathanasiou</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.265352</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Regression of Myocardial 99mTc-DPD Uptake After Tafamidis Treatment of Cardiac Transthyretin Amyloidosis]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1086</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Brief Communications</prism:section> <prism:startingPage>1083</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/79?rss=1&ssource=mfc"> <title><![CDATA[Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/79?rss=1&ssource=mfc</link> <description><![CDATA[Lisa Steinhelfer Jan 1, 2024; 65:79-84 Clinical Investigations]]></description> <dc:creator>Lisa Steinhelfer</dc:creator> <dc:date>2024-01-01</dc:date> <dc:identifier>10.2967/jnumed.123.265986</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy]]></dc:title> <prism:number>1</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>84</prism:endingPage> <prism:publicationDate>2024-01-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>79</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/731?rss=1&ssource=mfc"> <title><![CDATA[Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/731?rss=1&ssource=mfc</link> <description><![CDATA[Robert Seifert May 1, 2023; 64:731-737 Clinical Investigations]]></description> <dc:creator>Robert Seifert</dc:creator> <dc:date>2023-05-01</dc:date> <dc:identifier>10.2967/jnumed.122.264741</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis]]></dc:title> <prism:number>5</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>737</prism:endingPage> <prism:publicationDate>2023-05-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>731</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1252?rss=1&ssource=mfc"> <title><![CDATA[The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1252?rss=1&ssource=mfc</link> <description><![CDATA[Amir Karimzadeh Aug 1, 2023; 64:1252-1258 Clinical Investigations]]></description> <dc:creator>Amir Karimzadeh</dc:creator> <dc:date>2023-08-01</dc:date> <dc:identifier>10.2967/jnumed.122.265346</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy]]></dc:title> <prism:number>8</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1258</prism:endingPage> <prism:publicationDate>2023-08-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1252</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1831?rss=1&ssource=mfc"> <title><![CDATA[Total-Body Perfusion Imaging with [11C]-Butanol]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1831?rss=1&ssource=mfc</link> <description><![CDATA[Elizabeth J. Li Nov 1, 2023; 64:1831-1838 Clinical Investigations]]></description> <dc:creator>Elizabeth J. Li</dc:creator> <dc:date>2023-11-01</dc:date> <dc:identifier>10.2967/jnumed.123.265659</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Total-Body Perfusion Imaging with [11C]-Butanol]]></dc:title> <prism:number>11</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1838</prism:endingPage> <prism:publicationDate>2023-11-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1831</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1295?rss=1&ssource=mfc"> <title><![CDATA[MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1295?rss=1&ssource=mfc</link> <description><![CDATA[Lukas M. Carter Aug 1, 2023; 64:1295-1303 Special Contributions]]></description> <dc:creator>Lukas M. Carter</dc:creator> <dc:date>2023-08-01</dc:date> <dc:identifier>10.2967/jnumed.122.264230</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals]]></dc:title> <prism:number>8</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1303</prism:endingPage> <prism:publicationDate>2023-08-01</prism:publicationDate> <prism:section>Special Contributions</prism:section> <prism:startingPage>1295</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1164?rss=1&ssource=mfc"> <title><![CDATA[Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1164?rss=1&ssource=mfc</link> <description><![CDATA[Romain-David Seban Jul 1, 2023; 64:1164-1165 Letters]]></description> <dc:creator>Romain-David Seban</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.123.265434</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1165</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Letters</prism:section> <prism:startingPage>1164</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1024?rss=1&ssource=mfc"> <title><![CDATA[PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1024?rss=1&ssource=mfc</link> <description><![CDATA[Masatoshi Hotta Jul 1, 2023; 64:1024-1029 Featured Article of the Month]]></description> <dc:creator>Masatoshi Hotta</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.265242</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1029</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Featured Article of the Month</prism:section> <prism:startingPage>1024</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1202?rss=1&ssource=mfc"> <title><![CDATA[Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study)]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1202?rss=1&ssource=mfc</link> <description><![CDATA[Matteo Bauckneht Aug 1, 2024; 65:1202-1209 Clinical Investigations]]></description> <dc:creator>Matteo Bauckneht</dc:creator> <dc:date>2024-08-01</dc:date> <dc:identifier>10.2967/jnumed.124.267586</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study)]]></dc:title> <prism:number>8</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>1209</prism:endingPage> <prism:publicationDate>2024-08-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1202</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/117?rss=1&ssource=mfc"> <title><![CDATA[Clinical Value of 68Ga-Pentixafor PET/CT in Subtype Diagnosis of Primary Aldosteronism Patients with Adrenal Micronodules]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/1/117?rss=1&ssource=mfc</link> <description><![CDATA[Jie Ding Jan 1, 2024; 65:117-124 Clinical Investigations]]></description> <dc:creator>Jie Ding</dc:creator> <dc:date>2024-01-01</dc:date> <dc:identifier>10.2967/jnumed.123.266061</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Clinical Value of 68Ga-Pentixafor PET/CT in Subtype Diagnosis of Primary Aldosteronism Patients with Adrenal Micronodules]]></dc:title> <prism:number>1</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>124</prism:endingPage> <prism:publicationDate>2024-01-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>117</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1109?rss=1&ssource=mfc"> <title><![CDATA[An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1109?rss=1&ssource=mfc</link> <description><![CDATA[Julia Brosch-Lenz Jul 1, 2023; 64:1109-1116 Clinical Investigations]]></description> <dc:creator>Julia Brosch-Lenz</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.265094</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1116</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1109</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/618?rss=1&ssource=mfc"> <title><![CDATA[Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/618?rss=1&ssource=mfc</link> <description><![CDATA[Mahnoosh Naeimi Apr 1, 2023; 64:618-622 Clinical Investigations]]></description> <dc:creator>Mahnoosh Naeimi</dc:creator> <dc:date>2023-04-01</dc:date> <dc:identifier>10.2967/jnumed.122.264941</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers]]></dc:title> <prism:number>4</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>622</prism:endingPage> <prism:publicationDate>2023-04-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>618</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/5/735?rss=1&ssource=mfc"> <title><![CDATA[Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/5/735?rss=1&ssource=mfc</link> <description><![CDATA[Abuzar Moradi Tuchayi May 1, 2024; 65:735-739 Brief Communications]]></description> <dc:creator>Abuzar Moradi Tuchayi</dc:creator> <dc:date>2024-05-01</dc:date> <dc:identifier>10.2967/jnumed.123.266842</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval]]></dc:title> <prism:number>5</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>739</prism:endingPage> <prism:publicationDate>2024-05-01</prism:publicationDate> <prism:section>Brief Communications</prism:section> <prism:startingPage>735</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1744?rss=1&ssource=mfc"> <title><![CDATA[Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1744?rss=1&ssource=mfc</link> <description><![CDATA[Thomas A. Hope Nov 1, 2023; 64:1744-1747 Featured Article of the Month]]></description> <dc:creator>Thomas A. Hope</dc:creator> <dc:date>2023-11-01</dc:date> <dc:identifier>10.2967/jnumed.123.265916</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers]]></dc:title> <prism:number>11</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1747</prism:endingPage> <prism:publicationDate>2023-11-01</prism:publicationDate> <prism:section>Featured Article of the Month</prism:section> <prism:startingPage>1744</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/12/1876?rss=1&ssource=mfc"> <title><![CDATA[ChatGPT: Can You Prepare My Patients for [18F]FDG PET/CT and Explain My Reports?]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/12/1876?rss=1&ssource=mfc</link> <description><![CDATA[Julian M.M. Rogasch Dec 1, 2023; 64:1876-1879 Brief Communications]]></description> <dc:creator>Julian M.M. Rogasch</dc:creator> <dc:date>2023-12-01</dc:date> <dc:identifier>10.2967/jnumed.123.266114</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[ChatGPT: Can You Prepare My Patients for [18F]FDG PET/CT and Explain My Reports?]]></dc:title> <prism:number>12</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1879</prism:endingPage> <prism:publicationDate>2023-12-01</prism:publicationDate> <prism:section>Brief Communications</prism:section> <prism:startingPage>1876</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1721?rss=1&ssource=mfc"> <title><![CDATA[Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1721?rss=1&ssource=mfc</link> <description><![CDATA[Oliver Sartor Nov 1, 2023; 64:1721-1725 Brief Communications]]></description> <dc:creator>Oliver Sartor</dc:creator> <dc:date>2023-11-01</dc:date> <dc:identifier>10.2967/jnumed.123.266167</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers]]></dc:title> <prism:number>11</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1725</prism:endingPage> <prism:publicationDate>2023-11-01</prism:publicationDate> <prism:section>Brief Communications</prism:section> <prism:startingPage>1721</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/10/1610?rss=1&ssource=mfc"> <title><![CDATA[Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/10/1610?rss=1&ssource=mfc</link> <description><![CDATA[Alexandre Chicheportiche Oct 1, 2023; 64:1610-1616 Clinical Investigations]]></description> <dc:creator>Alexandre Chicheportiche</dc:creator> <dc:date>2023-10-01</dc:date> <dc:identifier>10.2967/jnumed.122.264923</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles]]></dc:title> <prism:number>10</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1616</prism:endingPage> <prism:publicationDate>2023-10-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1610</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1049?rss=1&ssource=mfc"> <title><![CDATA[Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1049?rss=1&ssource=mfc</link> <description><![CDATA[Kim M. Pabst Jul 1, 2023; 64:1049-1055 Clinical Investigations]]></description> <dc:creator>Kim M. Pabst</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.265215</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1055</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1049</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1456?rss=1&ssource=mfc"> <title><![CDATA[Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1456?rss=1&ssource=mfc</link> <description><![CDATA[Jens Hemmingsson Sep 1, 2023; 64:1456-1462 Clinical Investigations]]></description> <dc:creator>Jens Hemmingsson</dc:creator> <dc:date>2023-09-01</dc:date> <dc:identifier>10.2967/jnumed.123.265484</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment]]></dc:title> <prism:number>9</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1462</prism:endingPage> <prism:publicationDate>2023-09-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1456</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1069?rss=1&ssource=mfc"> <title><![CDATA[PSMA-GCK01: A Generator-Based 99mTc/188Re Theranostic Ligand for the Prostate-Specific Membrane Antigen]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1069?rss=1&ssource=mfc</link> <description><![CDATA[Jens Cardinale Jul 1, 2023; 64:1069-1075 Basic Science Investigations]]></description> <dc:creator>Jens Cardinale</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.264944</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[PSMA-GCK01: A Generator-Based 99mTc/188Re Theranostic Ligand for the Prostate-Specific Membrane Antigen]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1075</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Basic Science Investigations</prism:section> <prism:startingPage>1069</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1737?rss=1&ssource=mfc"> <title><![CDATA[Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1737?rss=1&ssource=mfc</link> <description><![CDATA[Vishnu Murthy Nov 1, 2023; 64:1737-1743 Clinical Investigations]]></description> <dc:creator>Vishnu Murthy</dc:creator> <dc:date>2023-11-01</dc:date> <dc:identifier>10.2967/jnumed.122.265155</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis]]></dc:title> <prism:number>11</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1743</prism:endingPage> <prism:publicationDate>2023-11-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1737</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1399?rss=1&ssource=mfc"> <title><![CDATA[Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1399?rss=1&ssource=mfc</link> <description><![CDATA[Xuetao Chen Sep 1, 2023; 64:1399-1405 Clinical Investigations]]></description> <dc:creator>Xuetao Chen</dc:creator> <dc:date>2023-09-01</dc:date> <dc:identifier>10.2967/jnumed.123.265530</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT]]></dc:title> <prism:number>9</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1405</prism:endingPage> <prism:publicationDate>2023-09-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1399</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/625?rss=1&ssource=mfc"> <title><![CDATA[Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/625?rss=1&ssource=mfc</link> <description><![CDATA[Xinying Hu Apr 1, 2023; 64:625-631 Clinical Investigations]]></description> <dc:creator>Xinying Hu</dc:creator> <dc:date>2023-04-01</dc:date> <dc:identifier>10.2967/jnumed.122.264638</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy]]></dc:title> <prism:number>4</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>631</prism:endingPage> <prism:publicationDate>2023-04-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>625</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/579?rss=1&ssource=mfc"> <title><![CDATA[Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/4/579?rss=1&ssource=mfc</link> <description><![CDATA[Pierre Olivier Apr 1, 2023; 64:579-585 Clinical Investigations]]></description> <dc:creator>Pierre Olivier</dc:creator> <dc:date>2023-04-01</dc:date> <dc:identifier>10.2967/jnumed.122.264743</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study]]></dc:title> <prism:number>4</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>585</prism:endingPage> <prism:publicationDate>2023-04-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>579</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/717?rss=1&ssource=mfc"> <title><![CDATA[Initial Results of 68Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/5/717?rss=1&ssource=mfc</link> <description><![CDATA[Philipp Backhaus May 1, 2023; 64:717-723 Clinical Investigations]]></description> <dc:creator>Philipp Backhaus</dc:creator> <dc:date>2023-05-01</dc:date> <dc:identifier>10.2967/jnumed.122.264871</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Initial Results of 68Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer]]></dc:title> <prism:number>5</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>723</prism:endingPage> <prism:publicationDate>2023-05-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>717</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1087?rss=1&ssource=mfc"> <title><![CDATA[Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1087?rss=1&ssource=mfc</link> <description><![CDATA[Nathaniel J. Smith Jul 1, 2023; 64:1087-1092 Clinical Investigations]]></description> <dc:creator>Nathaniel J. Smith</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.265149</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1092</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1087</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1036?rss=1&ssource=mfc"> <title><![CDATA[Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/7/1036?rss=1&ssource=mfc</link> <description><![CDATA[Christoph Berliner Jul 1, 2023; 64:1036-1042 Clinical Investigations]]></description> <dc:creator>Christoph Berliner</dc:creator> <dc:date>2023-07-01</dc:date> <dc:identifier>10.2967/jnumed.122.265252</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer]]></dc:title> <prism:number>7</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1042</prism:endingPage> <prism:publicationDate>2023-07-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1036</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1210?rss=1&ssource=mfc"> <title><![CDATA[Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/8/1210?rss=1&ssource=mfc</link> <description><![CDATA[Liang Zhao Aug 1, 2023; 64:1210-1217 Clinical Investigations]]></description> <dc:creator>Liang Zhao</dc:creator> <dc:date>2023-08-01</dc:date> <dc:identifier>10.2967/jnumed.122.265383</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types]]></dc:title> <prism:number>8</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1217</prism:endingPage> <prism:publicationDate>2023-08-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1210</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/10/1532?rss=1&ssource=mfc"> <title><![CDATA[Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/10/1532?rss=1&ssource=mfc</link> <description><![CDATA[Meiqi Wu Oct 1, 2023; 64:1532-1539 Clinical Investigations]]></description> <dc:creator>Meiqi Wu</dc:creator> <dc:date>2023-10-01</dc:date> <dc:identifier>10.2967/jnumed.123.265712</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib]]></dc:title> <prism:number>10</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1539</prism:endingPage> <prism:publicationDate>2023-10-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1532</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1690?rss=1&ssource=mfc"> <title><![CDATA[Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/11/1690?rss=1&ssource=mfc</link> <description><![CDATA[Maeve A. Hennessy Nov 1, 2023; 64:1690-1696 Clinical Investigations]]></description> <dc:creator>Maeve A. Hennessy</dc:creator> <dc:date>2023-11-01</dc:date> <dc:identifier>10.2967/jnumed.123.265853</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)]]></dc:title> <prism:number>11</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1696</prism:endingPage> <prism:publicationDate>2023-11-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1690</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/12/1899?rss=1&ssource=mfc"> <title><![CDATA[68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/12/1899?rss=1&ssource=mfc</link> <description><![CDATA[Ling Chen Dec 1, 2023; 64:1899-1905 Clinical Investigations]]></description> <dc:creator>Ling Chen</dc:creator> <dc:date>2023-12-01</dc:date> <dc:identifier>10.2967/jnumed.123.266079</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study]]></dc:title> <prism:number>12</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1905</prism:endingPage> <prism:publicationDate>2023-12-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>1899</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/2/252?rss=1&ssource=mfc"> <title><![CDATA[Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/2/252?rss=1&ssource=mfc</link> <description><![CDATA[Rainer Hamacher Feb 1, 2024; 65:252-257 Clinical Investigations]]></description> <dc:creator>Rainer Hamacher</dc:creator> <dc:date>2024-02-01</dc:date> <dc:identifier>10.2967/jnumed.123.266411</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor]]></dc:title> <prism:number>2</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>257</prism:endingPage> <prism:publicationDate>2024-02-01</prism:publicationDate> <prism:section>Clinical Investigations</prism:section> <prism:startingPage>252</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1320?rss=1&ssource=mfc"> <title><![CDATA[Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1320?rss=1&ssource=mfc</link> <description><![CDATA[Hongdi Li Aug 1, 2024; 65:1320-1326 Featured Article of the Month]]></description> <dc:creator>Hongdi Li</dc:creator> <dc:date>2024-08-01</dc:date> <dc:identifier>10.2967/jnumed.124.267767</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager]]></dc:title> <prism:number>8</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>1326</prism:endingPage> <prism:publicationDate>2024-08-01</prism:publicationDate> <prism:section>Featured Article of the Month</prism:section> <prism:startingPage>1320</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1166?rss=1&ssource=mfc"> <title><![CDATA[An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 3: Contribution from Calculating Absorbed Dose from Time-Integrated Activity]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/8/1166?rss=1&ssource=mfc</link> <description><![CDATA[Julia Brosch-Lenz Aug 1, 2024; 65:1166-1172 The State of the Art]]></description> <dc:creator>Julia Brosch-Lenz</dc:creator> <dc:date>2024-08-01</dc:date> <dc:identifier>10.2967/jnumed.123.267293</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 3: Contribution from Calculating Absorbed Dose from Time-Integrated Activity]]></dc:title> <prism:number>8</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>1172</prism:endingPage> <prism:publicationDate>2024-08-01</prism:publicationDate> <prism:section>The State of the Art</prism:section> <prism:startingPage>1166</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1352?rss=1&ssource=mfc"> <title><![CDATA[The Future of Nuclear Medicine in the United States]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;64/9/1352?rss=1&ssource=mfc</link> <description><![CDATA[Michael M. Graham Sep 1, 2023; 64:1352-1353 Issues and Controversies]]></description> <dc:creator>Michael M. Graham</dc:creator> <dc:date>2023-09-01</dc:date> <dc:identifier>10.2967/jnumed.122.265314</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[The Future of Nuclear Medicine in the United States]]></dc:title> <prism:number>9</prism:number> <prism:volume>64</prism:volume> <prism:endingPage>1353</prism:endingPage> <prism:publicationDate>2023-09-01</prism:publicationDate> <prism:section>Issues and Controversies</prism:section> <prism:startingPage>1352</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/9/1340?rss=1&ssource=mfc"> <title><![CDATA[177Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/9/1340?rss=1&ssource=mfc</link> <description><![CDATA[Andreas Poschenrieder Sep 1, 2024; 65:1340-1342 Is It Really Happening?]]></description> <dc:creator>Andreas Poschenrieder</dc:creator> <dc:date>2024-09-01</dc:date> <dc:identifier>10.2967/jnumed.124.267951</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[177Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?]]></dc:title> <prism:number>9</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>1342</prism:endingPage> <prism:publicationDate>2024-09-01</prism:publicationDate> <prism:section>Is It Really Happening?</prism:section> <prism:startingPage>1340</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/4/510?rss=1&ssource=mfc"> <title><![CDATA[Is 18F-FDG Metabolic Tumor Volume in Lymphoma Really Happening?]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/4/510?rss=1&ssource=mfc</link> <description><![CDATA[Sally F. Barrington Apr 1, 2024; 65:510-511 Is It Really Happening?]]></description> <dc:creator>Sally F. Barrington</dc:creator> <dc:date>2024-04-01</dc:date> <dc:identifier>10.2967/jnumed.123.267022</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[Is 18F-FDG Metabolic Tumor Volume in Lymphoma Really Happening?]]></dc:title> <prism:number>4</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>511</prism:endingPage> <prism:publicationDate>2024-04-01</prism:publicationDate> <prism:section>Is It Really Happening?</prism:section> <prism:startingPage>510</prism:startingPage> </item> <item rdf:about="http://jnm.snmjournals.org/cgi/content/short/jnumed;65/4/540?rss=1&ssource=mfc"> <title><![CDATA[PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3]]></title> <link>http://jnm.snmjournals.org/cgi/content/short/jnumed;65/4/540?rss=1&ssource=mfc</link> <description><![CDATA[Thomas A. Hope Apr 1, 2024; 65:540-540 Editorials]]></description> <dc:creator>Thomas A. Hope</dc:creator> <dc:date>2024-04-01</dc:date> <dc:identifier>10.2967/jnumed.123.267042</dc:identifier> <dc:publisher>Society of Nuclear Medicine</dc:publisher> <dc:title><![CDATA[PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3]]></dc:title> <prism:number>4</prism:number> <prism:volume>65</prism:volume> <prism:endingPage>540</prism:endingPage> <prism:publicationDate>2024-04-01</prism:publicationDate> <prism:section>Editorials</prism:section> <prism:startingPage>540</prism:startingPage> </item> </rdf:RDF>